LONDON, May 20 (Reuters) - AstraZeneca’s confidence in its promising new drugs may have seen off Pfizer’s $118 billion takeover bid for now, but investors are left contemplating the lessons from 2004, when it was also trumpeting its product pipeline. AstraZeneca became renowned a decade ago for talking up the prospects for its new treatments under former chief executive Tom McKillop, only to see key experimental medicines tumble like ninepins in a series of development setbacks.
Hey, check out all the research scientist jobs. Post your resume today!
